Population-based outcomes of patients (pt) with early-stage HER2-positive breast cancer treated with adjuvant trastuzumab (T)

Autor:	Joy McCarthy, Krista Noonan
Rok vydání:	2012
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Population based medicine.disease Breast cancer Trastuzumab Internal medicine HER2 Positive Breast Cancer medicine Clinical efficacy Stage (cooking) business Adjuvant medicine.drug
Zdroj:	Journal of Clinical Oncology. 30:e11079-e11079
ISSN:	1527-7755 0732-183X
Popis:	e11079 Background: Phase III trials have shown clinical efficacy of T when combined with chemotherapy in HER2-positive early stage breast cancer, decreasing recurrence by 50% and increasing survival by 30%. 15-20% of early stage breast cancers demonstrate amplification of the HER2 gene, which is associated with a poor prognosis. The aims of this study were to evaluate the clinical effectiveness of T, and explore potential prognostic factors. Methods: Pts with stage I-III breast cancer overexpressing HER2 from 2005 to 2010, assessed in Newfoundland and Labrador’s cancer centre were retrospectively identified from the Provincial Tumour Registry. Pt, treatment, and tumour characteristics were extracted. Kaplan-Meier curves were used for survival analysis, and Cox Proportional Hazards Models were used to identify prognostic factors and evaluate their impact on outcomes. Results: A total of 148 pts were identified. The median age was 56 years, and 76% received T. At a median follow-up of 25 months, overall survival (OS) was 97% (p=0.0002), and disease-free survival was 96% (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2e243e7ca81779eae63658a2d5ddaee2 https://doi.org/10.1200/jco.2012.30.15_suppl.e11079 Zobrazit plný text záznamu